PSTX - Poseida Therapeutics GAAP EPS of -$0.93 misses by $0.26 revenue of $1.44M beats by $0.61M
Poseida Therapeutics press release (NASDAQ:PSTX): Q1 GAAP EPS of -$0.93 misses by $0.26. Revenue of $1.44M beats by $0.61M. As of March 31, 2022, the Company's cash and cash equivalents balance was $183.5 million.
For further details see:
Poseida Therapeutics GAAP EPS of -$0.93 misses by $0.26, revenue of $1.44M beats by $0.61M